BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 16210961)

  • 1. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients.
    Kahan BD; Yakupoglu YK; Schoenberg L; Knight RJ; Katz SM; Lai D; Van Buren CT
    Transplantation; 2005 Sep; 80(6):749-58. PubMed ID: 16210961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation.
    Kahan BD; Podbielski J; Napoli KL; Katz SM; Meier-Kriesche HU; Van Buren CT
    Transplantation; 1998 Oct; 66(8):1040-6. PubMed ID: 9808489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation.
    Knight RJ; Podder H; Kerman RH; Lawless A; Katz SM; Van Buren CT; Gaber AO; Kahan BD
    Transplantation; 2010 Mar; 89(6):727-32. PubMed ID: 20195219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individualization of immunosuppressive therapy. III. Sirolimus associated with a reduced incidence of malignancy.
    Yakupoglu YK; Buell JF; Woodle S; Kahan BD
    Transplant Proc; 2006 Mar; 38(2):358-61. PubMed ID: 16549120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Median effect analysis of efficacy versus adverse effects of immunosuppressants.
    Kahan BD; Kramer WG
    Clin Pharmacol Ther; 2001 Jul; 70(1):74-81. PubMed ID: 11452247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
    Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
    Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion to sirolimus in kidney transplant recipients: a single-center study.
    Ganji MR; Hakemi MS; Esfehani F; Alatab S; Naderi GH
    Iran J Kidney Dis; 2013 Jul; 7(4):309-15. PubMed ID: 23880809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
    Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
    Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. De novo hemolytic uremic syndrome after kidney transplantation in patients treated with cyclosporine-sirolimus combination.
    Langer RM; Van Buren CT; Katz SM; Kahan BD
    Transplantation; 2002 Mar; 73(5):756-60. PubMed ID: 11907423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
    Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of sirolimus treatment in kidney allograft recipients with prolonged cold ischemia times: 5-year outcomes.
    Boratynska M; Banasik M; Patrzalek D; Klinger M
    Exp Clin Transplant; 2008 Mar; 6(1):59-66. PubMed ID: 18405247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sirolimus does not increase the risk for postoperative thromboembolic events among renal transplant recipients.
    Langer RM; Kahan BD
    Transplantation; 2003 Jul; 76(2):318-23. PubMed ID: 12883185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
    Oh CK; Huh KH; Ha J; Kim YH; Kim YL; Kim YS
    Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.
    Gonwa TA; Hricik DE; Brinker K; Grinyo JM; Schena FP;
    Transplantation; 2002 Dec; 74(11):1560-7. PubMed ID: 12490789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effectiveness and safety of conversion therapy with the combination of sirolimus with low dose cyclosporine in renal transplantation recipients: a five-year clinical observation].
    Zhu L; Ding T; Wang XX; Lin ZB; Chen G
    Zhonghua Yi Xue Za Zhi; 2016 May; 96(20):1556-61. PubMed ID: 27266681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine.
    Flechner SM; Goldfarb D; Modlin C; Feng J; Krishnamurthi V; Mastroianni B; Savas K; Cook DJ; Novick AC
    Transplantation; 2002 Oct; 74(8):1070-6. PubMed ID: 12438948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis.
    Chueh SC; Kahan BD
    Transplantation; 2003 Jul; 76(2):375-82. PubMed ID: 12883196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term Follow-up of Kidney Transplant Recipients in the Spare-the-Nephron-Trial.
    Weir MR; Pearson TC; Patel A; Peddi VR; Kalil R; Scandling J; Chan L; Baliga P; Melton L; Mulgaonkar S; Waid T; Schaefer H; Youssef N; Anandagoda L; McCollum D; Lawson S; Gordon R
    Transplantation; 2017 Jan; 101(1):157-165. PubMed ID: 26950714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.